4.7 Article

CD40 on NOD CD4 T cells contributes to their activation and pathogenicity

Journal

JOURNAL OF AUTOIMMUNITY
Volume 31, Issue 4, Pages 385-392

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2008.09.001

Keywords

CD40; NOD; Type 1 diabetes; CD4 T cells

Categories

Funding

  1. Juvenile Diabetes Research Foundation (JDRF) [1-2004-113]
  2. American Diabetes Association

Ask authors/readers for more resources

Our goals in this study were to investigate conditions under which T cells from NOD mice express CD40 and to determine how CD40 on autoreactive CD4 T cells contributes to their pathogenicity in T1D. Using CD40-positive diabetogenic T cell clones and CD4 T cells from NOD mice, we examined expression of CD40 upon activation through the TCR and costimulation through either CD28 or CD40. Our results indicate that CD40 expression is increased upon activation with antigen/MHC and that activation of NOD CD4 T cells through TCR/CD40 rapidly induced CD40 expression. Furthermore, CD40 costimulation promoted T cell proliferation to the same extent as costimulation through TCR/CD28. Importantly, costimulation of CD4 T cells through CD40 also interfered with T cell homeostasis by altering regulation of CTLA-4 expression. Through CD40-CD154 blocking studies, we demonstrated that signaling between T cells through CD40 and its ligand contributes to activation of pathogenic T cells and that blocking CD40 on T cells abrogates their ability to transfer diabetes. Thus, costimulation through CD40 on NOD T cells contributes to their pathogenicity by providing additional pathways for activation and by inhibiting upregulation of CTLA-4 during T cell activation. (C) 2008 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells

Braxton L. Jamison, Tobias Neef, Andrew Goodspeed, Brenda Bradley, Rocky L. Baker, Stephen D. Miller, Kathryn Haskins

JOURNAL OF IMMUNOLOGY (2019)

Article Endocrinology & Metabolism

Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes

Rocky L. Baker, Marynette Rihanek, Anita C. Hohenstein, Maki Nakayama, Aaron Michels, Peter A. Gottlieb, Kathryn Haskins, Thomas Delong

DIABETES (2019)

Review Endocrinology & Metabolism

Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes

Rocky L. Baker, Braxton L. Jamison, Kathryn Haskins

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2019)

Article Endocrinology & Metabolism

Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01

David Arribas-Layton, Perrin Guyer, Thomas Delong, Mylinh Dang, I-Ting Chow, Cate Speake, Carla J. Greenbaum, William W. Kwok, Rocky L. Baker, Kathryn Haskins, Eddie A. James

DIABETES (2020)

Meeting Abstract Endocrinology & Metabolism

Reducing Autoinflammation: The Impact of T-Cell Deficiency on Atherosclerosis

Alyssa J. Shepherd, Martin Yussman, David H. Wagner, Gisela M. Vaitaitis

DIABETES (2022)

Meeting Abstract Endocrinology & Metabolism

A Novel Drug to Modulate Autoinflammation and Promote Glucose Control in Type 1 Diabetes Mellitus

David H. Wagner, Gisela M. Vaitaitis

DIABETES (2022)

Article Immunology

CD40 Drives Central Nervous System Autoimmune Disease by Inducing Complementary Effector Programs via B Cells and Dendritic Cells

Ying Lu, Max Xu, Cayce E. Dorrier, Ray Zhang, Christian T. Mayer, David Wagner, Dorian B. McGavern, Richard J. Hodes

Summary: CD40 plays an essential role in driving autoimmune diseases in the central nervous system (CNS). It orchestrates distinct effector programs in dendritic cells (DCs) and B cells, leading to the activation of pathogenic T cells and the production of disease-causing antibodies, respectively.

JOURNAL OF IMMUNOLOGY (2022)

Article Immunology

Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS)

Christian Curran, Gisela Vaitaitis, Dan Waid, Timothy Volmer, Enrique Alverez, David H. Wagner

Summary: Treating multiple sclerosis has been challenging, but Ocrelizumab has shown success in treating both chronic relapsing and progressive forms of the disease. In a study, it was found that TH40 cells, which are pathogenic effector T cells, increased in number during the earliest stage of multiple sclerosis (clinically isolated syndrome) and remained expanded in progressive forms of the disease. However, treatment with Ocrelizumab reduced TH40 cell numbers to healthy levels and decreased the production of inflammatory cytokines.

JOURNAL OF NEUROIMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15

Gisela M. Vaitaitis, David H. Wagner Jr

Summary: CD40 signaling is an important target in autoimmunity. Blocking the CD40-CD154 pathway using monoclonal antibodies during clinical trials led to severe adverse events. A peptide called KGYY15 has shown promise in preventing type 1 diabetes and reversing hyperglycemia by normalizing effector T-cell levels. The peptide also interacts with integrins CD11a/CD18 and CD11b/CD18, complicating our understanding of the inflammatory nexus and how to prevent autoinflammation.

JOURNAL OF BIOLOGICAL CHEMISTRY (2023)

Article Immunology

Importance of CD40/CD40 dyad in the course of infection with Trypanosoma cruzi: Impact of its inhibition

Fernanda M. Frank, David H. Wagner Jr, Miriam Postan, Patricia B. Petray

Summary: The CD40/CD40L interaction plays a dual role in Trypanosoma cruzi infection, depending on the timing of treatment initiation. Early treatment with CD40-targeted peptide leads to uncontrolled acute infection and marked tissue damage, while late treatment improves myocardial and skeletal muscle damage.

MICROBIAL PATHOGENESIS (2023)

Meeting Abstract Immunology

CD40 on B cells and on dendritic cells mediates experimental autoimmune encephalomyelitis pathogenesis through distinct and complementary mechanisms

Ying Lu, Max Xu, Ray Zhang, David H. Wagner, Richard Hodes

JOURNAL OF IMMUNOLOGY (2021)

Meeting Abstract Medicine, General & Internal

CD20 EXPRESSION IS ELEVATED ON A T HELPER CELL SUBPOPULATION IN NEWLY DIAGNOSED MULTIPLE SCLEROSIS PATIENTS

C. D. Curran, D. H. Wagner, T. L. Vollmer

JOURNAL OF INVESTIGATIVE MEDICINE (2020)

Article Endocrinology & Metabolism

Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes

Ercument Dirice, Sevim Kahraman, Dario F. De Jesus, Abdelfattah El Ouaamari, Giorgio Basile, Rocky L. Baker, Burcu Yigit, Paul D. Piehowski, Mi-Jeong Kim, Alexander J. Dwyer, Raymond W. S. Ng, Cornelia Schuster, Heidrun Vethe, Tijana Martinov, Yuki Ishikawa, Adrian Kee Keong Teo, Richard D. Smith, Jiang Hu, Kathryn Haskins, Thomas Serwold, Wei-Jun Qian, Brian T. Fife, Stephan Kissler, Rohit N. Kulkarni

NATURE METABOLISM (2019)

Meeting Abstract Immunology

Controlling the Residual Inflammatory Risk in Type 1 Diabetic Atherosclerosis

Martin Yussman, David H. Wagner, Gisela Vaitaitis, Dan Waid

JOURNAL OF IMMUNOLOGY (2019)

Meeting Abstract Immunology

Peripheral Blood Th40 cells Reflect Disease Progression and Are Controlled by Rituximab in Human Multiple Sclerosis

David H. Wagner, Gisela Vaitaitis, Dan Waid

JOURNAL OF IMMUNOLOGY (2019)

Article Immunology

Isolation and characterisation of PR3-specific B cells and their immunoglobulin sequences

Shane Kelly, Katherine J. L. Jackson, Timothy J. Peters, Dan Suan, Christopher C. Goodnow

Summary: This study successfully identified and characterized PR3-specific B cells from the peripheral blood of patients with PR3 autoantibodies. These cells exhibited specific immunological features, suggesting that PR3 self-reactivity may occur early in B-cell development.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Targeting NF-κB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis

Ana Merino-Vico, Jan Piet van Hamburg, Paul Tuijnenburg, Giulia Frazzei, Aram Al-Soudi, Carlo G. Bonasia, Boy Helder, Abraham Rutgers, Wayel H. Abdulahad, Coen A. Stegeman, Jan-Stephan Sanders, Laura Bergamaschi, Paul A. Lyons, Theo Bijma, Laura van Keep, Kirsten Wesenhagen, Aldo Jongejan, Henric Olsson, Niek de Vries, Taco W. Kuijpers, Peter Heeringa, Sander W. Tas

Summary: B lineage cells play a critical role in ANCA-associated vasculitis (AAV), and the transcription factor NF-kappa B may be a potential therapeutic target for AAV and other autoimmune diseases with prominent B cell involvement.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies

Christopher Nelke, Thomas Muentefering, Derya Cengiz, Lukas Theissen, Vera Dobelmann, Christina B. Schroeter, Helena Block, Corinna Preu, Alexander P. E. Michels, Stefanie Lichtenberg, Marc Pawlitzki, Steffen Pfeuffer, Niklas Huntemann, Alexander Zarbock, Thorben Briese, Christoph Kittl, Carsten Dittmayer, Thomas Budde, Ingrid E. Lundberg, Werner Stenzel, Sven G. Meuth, Tobias Ruck

Summary: K2P2.1 plays a regulatory role in the autoimmune response of idiopathic inflammatory myopathies (IIMs), by regulating inflammatory cell response, adhesion, and transmigration in both endothelial and skeletal muscle cells. Inhibiting K2P2.1 enhances the inflammatory response, while activating K2P2.1 improves the disease course.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis

Xuan Zhang, Jun Xia, Ying Jiang, David S. Pisetsky, Josef S. Smolen, Rong Mu, Shengming Dai, Michael E. Weinblatt, Tore K. Kvien, Juan Li, Thomas Doerner, Yu Zhang, Liwei Lu, Chengde Yang, Pingting Yang, Yuan Zhang, Chenchen Xu, Zhan Zhao, Peter E. Lipsky

Summary: The study suggests that TwHF may be as effective as MTX in treating active RA, and combination therapy may be more effective than monotherapy.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Novel and unique rheumatoid factors cross-react with viral epitopes in COVID-19

Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, Zihao Zheng, Alex M. Robbins, S. Janna Bashar, Michael F. Denny, Sara S. Mccoy, Irene M. Ong, Miriam A. Shelef

Summary: Rheumatoid factors (RFs) are polyreactive antibodies that can bind disease-specific epitopes. Recent studies have found that RFs in COVID-19 can bind novel IgG epitopes, which provides new insights into the mechanism of RFs.

JOURNAL OF AUTOIMMUNITY (2024)

Article Immunology

Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study

Johanne Liberatore, Yann Nguyen, Jerome Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puechal, Loic Guillevin, Benjamin Terrier

Summary: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) can lead to decreased gammaglobulin levels, which is associated with an increased risk of relapse and severe infections. Older age, low gammaglobulin levels, and receiving pulses of methylprednisolone at induction therapy are risk factors for gammaglobulin decline.

JOURNAL OF AUTOIMMUNITY (2024)